Boundless Bio Inc (OQ:BOLD)

Apr 11, 2024 08:00 am ET
Boundless Bio Announces First Patient Dosed in First-in-Human Phase 1/2 Clinical Trial of BBI-825 in Cancer Patients with Resistance Gene Amplifications
Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced that the first patient has been dosed with BBI-825 in a first-in-human, Phase 1/2 clinical trial for
Apr 08, 2024 08:00 am ET
Boundless Bio Presents Preclinical and Clinical Pharmacodynamic Data on its Lead Extrachromosomal DNA (ecDNA)-Directed Therapy, BBI-355, at the American Association for Cancer Research Annual Meeting
Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, presents preclinical and clinical pharmacodynamic data on its lead ecDNA-directed therapy (ecDTx), BBI-355, and research on ecDNA-mediated acquired resistance to chemotherapy at the American Association for Cancer Research (AACR) Annual Meeting 2024. BBI-355 is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1) being studied in the ongoing, first-in-human, Phase 1/
Mar 27, 2024 06:55 pm ET
Boundless Bio Announces Pricing of Initial Public Offering
Boundless Bio, Inc. (Nasdaq: BOLD), a clinical stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced the pricing of its initial public offering of 6,250,000 shares of its common stock at an initial public offering price of $16.00 per share. All of the shares are being offered by Boundless Bio. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses, are expected to be $100.0 million. Boundle
Dec 23, 2019 09:00 am ET
LOGM, ARQL, TIF, and BOLD SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of Buyouts
Rigrodsky & Long, P.A. announces that it is investigating: LogMeIn, Inc. (NASDAQ GS: LOGM) regarding possible breaches of fiduciary duties and other violations of law related to LogMeIn’s agreement to be acquired by affiliates of Francisco...
Dec 21, 2019 11:44 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates Whether The Sale Of These Companies Is Fair To Shareholders – BOLD, INST, THOR
Halper Sadeh LLP, a global investor rights law firm, continues to investigate the following companies: Audentes Therapeutics, Inc. (NASDAQ: BOLD) The investigation concerns whether Audentes and its board of directors violated the federal...
Dec 16, 2019 07:30 pm ET
TECD, TIF, BOLD, and WLH SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of Buyouts
Rigrodsky & Long, P.A. announces that it is investigating: Tech Data Corporation (NASDAQ GS: TECD) regarding possible breaches of fiduciary duties and other violations of law related to Tech Data’s agreement to be acquired by an affiliate of the...
Dec 16, 2019 02:42 pm ET
AUDENTES ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of BOLD and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized stockholder law firm, has launched an investigation into whether the board members of Audentes Therapeutics, Inc. (NASDAQ:BOLD) breached their fiduciary duties or violated the federal securities laws in connection with the company’s proposed sale to Astellas Pharma Inc.
Dec 16, 2019 08:00 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates Whether The Sale Of These Companies Is Fair To Shareholders – BOLD, AKS, INST, THOR
Halper Sadeh LLP, a global investor rights law firm, continues to investigate the following companies: Audentes Therapeutics, Inc. (NASDAQ: BOLD)The investigation concerns whether Audentes and its board of directors violated the federal securities...
Dec 10, 2019 09:30 pm ET
BOLD, MDCO, AYR, and PEGI SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of Buyouts
Rigrodsky & Long, P.A. announces that it is investigating: Audentes Therapeutics, Inc. (NASDAQ GS: BOLD) regarding possible breaches of fiduciary duties and other violations of law related to Audentes Therapeutics’ agreement to be acquired by...
Dec 10, 2019 11:51 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates Whether The Sale Of These Companies Is Fair To Shareholders – INST, AKS, BOLD, SORL
Halper Sadeh LLP, a global investor rights law firm, continues to investigate the following companies: Instructure, Inc. (NYSE: INST)The investigation concerns whether Instructure and its board of directors violated the federal securities laws...
Dec 02, 2019 11:10 pm ET
Audentes Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Audentes Therapeutics, Inc. is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – BOL
Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Audentes Therapeutics, Inc. (NASDAQ: BOLD) to Astellas Pharma Inc. (“Astellas”) for $60.00 per share is fair to Audentes shareholders. On behalf of Audentes...
Dec 02, 2019 06:01 pm ET
Astellas Enters into Definitive Agreement to Acquire Audentes Therapeutics
Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and Audentes Therapeutics, Inc. (NASDAQ: BOLD, Chairman and CEO: Matthew R. Patterson, “Audentes”), today announced that they have entered into a definitive agreement for Astellas to acquire Audentes at a price of US$60.00 per share in cash, representing a total equity value of approximately US$3 billion.
Nov 26, 2019 04:01 pm ET
Audentes Therapeutics to Participate in Upcoming Investor Conferences
Audentes Therapeutics, Inc. (Nasdaq: BOLD), a leading AAV-based genetic medicines company focused on developing and commercializing innovative products for serious rare neuromuscular diseases, today announced that Natalie Holles, President and Chief Operating Officer, will participate in the following investor conferences in December:
Nov 07, 2019 04:01 pm ET
Audentes Therapeutics Reports Third Quarter 2019 Financial Results and Provides Corporate Update
Audentes Therapeutics, Inc. (Nasdaq: BOLD), a leading AAV-based genetic medicines company focused on developing and commercializing innovative products for serious rare neuromuscular diseases, today reported its financial results for the third quarter ended September 30, 2019, and provided an update on the company’s recent achievements and anticipated upcoming milestones.
Oct 31, 2019 07:00 am ET
Audentes Therapeutics to Release Third Quarter 2019 Financial Results and Provide Corporate Update on Thursday, November 7, 2019
Audentes Therapeutics, Inc. (Nasdaq: BOLD), a leading AAV-based genetic medicines company focused on developing and commercializing innovative products for serious rare neuromuscular diseases, will host a conference call and webcast to report its third quarter 2019 financial results and provide a corporate update on Thursday, November 7, 2019.
Oct 05, 2019 07:01 am ET
Audentes Therapeutics Presents New Positive Data from ASPIRO, the Clinical Trial Evaluating AT132 in Patients with X-Linked Myotubular Myopathy (XLMTM), at the 24th International Annual Congress of th
Audentes Therapeutics, Inc. (Nasdaq: BOLD), a leading AAV-based genetic medicines company focused on developing and commercializing innovative products for serious rare neuromuscular diseases, today announced new positive data from ASPIRO, the clinical trial evaluating AT132 in patients with X-Linked Myotubular Myopathy (XLMTM). The data are being presented today at the 24th International Annual Congress of the World Muscle Society by Dr. James J. Dowling, Hospital for Sick Children, Toronto, Canada, during the Clinical Trial Highlights 7 session scheduled to begin at 1:00pm Central European S
Oct 04, 2019 06:00 pm ET
Audentes Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Audentes Therapeutics, Inc. (Nasdaq: BOLD), a leading AAV-based genetic medicines company focused on developing and commercializing innovative products for serious rare neuromuscular diseases, announced it has granted equity awards that were previously approved by the Compensation Committee of its Board of Directors under the Audentes Therapeutics, Inc. 2018 Equity Inducement Plan, as a material inducement to employment to twenty-one individuals hired by Audentes in September 2019. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
Oct 01, 2019 08:00 am ET
Audentes Therapeutics to Participate in Upcoming Investor Conferences
Audentes Therapeutics, Inc. (Nasdaq: BOLD), a leading AAV-based genetic medicines company focused on developing and commercializing innovative products for serious rare neuromuscular diseases, today announced that Natalie Holles, President and Chief Operating Officer, will participate in the following investor conferences in October:
Sep 30, 2019 08:00 am ET
Audentes Announces Upcoming Presentations at the 24th International Annual Congress of the World Muscle Society, Including New Data From ASPIRO, the Clinical Trial Evaluating AT132 in Patients With X-
Audentes Therapeutics, Inc. (Nasdaq: BOLD), a leading AAV-based genetic medicines company focused on developing and commercializing innovative products for serious rare neuromuscular diseases, today announced its planned presentations at the 24th International Annual Congress of the World Muscle Society in Copenhagen, Denmark, including new data from ASPIRO, the clinical trial evaluating AT132 in patients with X-linked Myotubular Myopathy. The oral presentation will be given by Dr. James J. Dowling, Hospital for Sick Children, Toronto, Canada, and will be held during the Clinical Trial Highlig
Sep 06, 2019 06:00 pm ET
Audentes Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Audentes Therapeutics, Inc. (Nasdaq: BOLD), a leading AAV-based genetic medicines company focused on developing and commercializing innovative products for serious rare neuromuscular diseases, announced it has granted equity awards that were previously approved by the Compensation Committee of its Board of Directors under the Audentes Therapeutics, Inc. 2018 Equity Inducement Plan, as a material inducement to employment to seventeen individuals hired by Audentes from July 16 through August 31, 2019. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
Aug 26, 2019 08:00 am ET
Audentes Therapeutics to Participate in Upcoming Investor Conferences
SAN FRANCISCO, Aug. 26, 2019 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a leading AAV-based genetic medicines company focused on developing and commercializing innovative products for serious rare neuromuscular diseases, today announced that it will participate in the following investor conferences in September:
Aug 06, 2019 04:01 pm ET
Audentes Therapeutics Reports Second Quarter 2019 Financial Results and Provides Corporate Update
SAN FRANCISCO, Aug. 6, 2019 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a leading AAV-based genetic medicines company focused on developing and commercializing innovative products for serious rare neuromuscular diseases, today reported its financial results for the second quarter ended June 30, 2019 and provided an update on the company's recent achievements and anticipated upcoming milestones.
Aug 01, 2019 08:00 am ET
Audentes Therapeutics to Participate in Upcoming Investor Conferences
SAN FRANCISCO, Aug. 1, 2019 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a leading AAV-based genetic medicines company focused on developing and commercializing innovative products for serious rare neuromuscular diseases, today announced that it will participate in the following investor conferences in August:
Jul 30, 2019 08:00 am ET
Audentes Therapeutics to Release Second Quarter 2019 Financial Results and Provide Corporate Update on Tuesday, August 6, 2019
SAN FRANCISCO, July 30, 2019 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a leading AAV-based genetic medicines company focused on developing and commercializing innovative products for serious rare neuromuscular diseases, will host a conference call and webcast to report its second quarter 2019 financial results and provide a corporate update on Tuesday, August 6, 2019.
Jul 19, 2019 06:00 pm ET
Audentes Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, July 19, 2019 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a leading AAV-based genetic medicines company focused on developing and commercializing innovative products for serious rare neuromuscular diseases, announced it has granted equity awards that were previously approved by the Compensation Committee of its Board of Directors under the Audentes Therapeutics, Inc. 2018 Equity Inducement Plan, as a material inducement to employment to ten individuals hired by Audentes from June 1 through July 15, 2019. The equity awards were approved in accordance with Nas
May 08, 2019 08:00 am ET
Audentes Therapeutics to Participate in the Bank of America Merrill Lynch 2019 Health Care Conference
SAN FRANCISCO, May 8, 2019 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a leading AAV-based genetic medicines company focused on developing and commercializing innovative products for serious rare neuromuscular diseases, today announced that it will participate in the Bank of America Merrill Lynch Health Care Conference, taking place May 15-17 in Las Vegas, NV. 
May 07, 2019 04:01 pm ET
Audentes Therapeutics Reports First Quarter 2019 Financial Results and Provides Corporate Update
SAN FRANCISCO, May 7, 2019 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a leading AAV-based genetic medicines company focused on developing and commercializing innovative products for serious rare neuromuscular diseases, today reported its financial results for the first quarter ended March 31, 2019 and provided an update on the company's recent achievements and anticipated upcoming milestones.  
May 01, 2019 02:15 pm ET
Audentes Therapeutics Presents New Positive Data from ASPIRO, the Phase 1/2 Clinical Trial of AT132 for X-linked Myotubular Myopathy, at 22nd Annual Meeting of the American Society of Gene and Cell Th
SAN FRANCISCO, May 1, 2019 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a leading AAV-based genetic medicines company focused on developing and commercializing innovative products for serious rare neuromuscular diseases, today announced new positive data from ASPIRO, the Phase 1/2 clinical trial of AT132 for the treatment of X-linked Myotubular Myopathy (XLMTM).  The data are being presented today at the 22nd Annual Meeting of the American Society of Gene and Cell Therapy by Perry B. Shieh, M.D., Ph.D., Associate Professor of Neurology, University of California Los Angeles and
Apr 30, 2019 08:00 am ET
Audentes Therapeutics to Release First Quarter 2019 Financial Results and Provide Corporate Update on Tuesday, May 7, 2019
SAN FRANCISCO, April 30, 2019 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a leading AAV-based genetic medicines company focused on developing and commercializing innovative products for serious rare neuromuscular diseases, will host a conference call and webcast to report its first quarter 2019 financial results and provide a corporate update on Tuesday, May 7, 2019.
Apr 26, 2019 06:00 pm ET
Audentes Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, April 26, 2019 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing innovative gene therapy products for patients living with serious, life-threatening rare diseases, announced it has granted equity awards on April 24, 2019, that were previously approved by the Compensation Committee of its Board of Directors under the Audentes Therapeutics, Inc. 2018 Equity Inducement Plan, as a material inducement to employment to nine individuals hired by Audentes from April 2 through April 24, 2019. The equity awar
Apr 23, 2019 08:00 am ET
Audentes Therapeutics Announces Launch of New State-of-the-Art Internal cGMP Plasmid Manufacturing Facility
SAN FRANCISCO, April 23, 2019 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a leading AAV-based genetic medicines company focused on developing and commercializing innovative products for serious rare neuromuscular diseases, today announced the launch of a new state-of-the-art, internal cGMP plasmid manufacturing facility in South San Francisco. This new internal capability is expected to significantly enhance a critical element of the company's supply chain, providing high-quality nonclinical and cGMP-grade plasmids for all of its development programs. 
Apr 15, 2019 04:01 pm ET
Audentes Therapeutics Announces Upcoming Presentations at 22nd Annual Meeting of the American Society of Gene and Cell Therapy Including New Data from ASPIRO, the Phase 1/2 Clinical Trial of AT132 in
SAN FRANCISCO, April 15, 2019 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a leading AAV-based genetic medicines company focused on developing and commercializing innovative products for serious rare neuromuscular diseases, today announced multiple planned presentations at the 22nd Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) in Washington, D.C., including new data from ASPIRO, the Phase 1/2 Clinical Trial of AT132 in patients with X-linked Myotubular Myopathy (XLMTM).  The oral presentation will be given by Perry B. Shieh, M.D., Ph.D., Associate Pro
Apr 05, 2019 06:00 pm ET
Audentes Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, April 5, 2019 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing innovative gene therapy products for patients living with serious, life-threatening rare diseases, announced it has granted equity awards on April 3, 2019, that were previously approved by the Compensation Committee of its Board of Directors under the Audentes Therapeutics, Inc. 2018 Equity Inducement Plan, as a material inducement to employment to sixteen individuals hired by Audentes from March 1 through April 1, 2019. The equity awards
Apr 01, 2019 08:00 am ET
Audentes Therapeutics Appoints Legal and Corporate Communications Executives; Promotes Thomas P. Soloway to Executive Vice President and Chief Financial Officer
SAN FRANCISCO, April 1, 2019 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing innovative gene therapy products for patients living with serious, life-threatening rare diseases, today announced that Mark A. Meltz, J.D. has joined the company as Senior Vice President, General Counsel and Sarah J. Spencer has joined the company as Vice President, Corporate Communications.  In addition, Thomas P. Soloway, currently Senior Vice President, Chief Financial Officer, has been promoted to the newly created position of Executi
Mar 29, 2019 07:25 am ET
Factors of Influence in 2019, Key Indicators and Opportunity within Nutanix, Steel Dynamics, Audentes Therapeutics, Comfort Systems, LHC Group, and Cambrex — New Research Emphasizes Economic Growth
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Nutanix Inc. (NASDAQ:NTNX), Steel Dynamics, Inc. (NASDAQ:STLD),...
Mar 08, 2019 05:00 pm ET
Audentes Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, March 8, 2019 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing innovative gene therapy products for patients living with serious, life-threatening rare diseases, announced it has granted equity awards on March 7, 2019, that were previously approved by the Compensation Committee of its Board of Directors under the Audentes Therapeutics, Inc. 2018 Equity Inducement Plan, as a material inducement to employment to six individuals hired by Audentes in February 2019. The equity awards were approved in accor
Feb 28, 2019 07:00 am ET
Audentes Therapeutics Recognizes Rare Disease Day by Launching "Be Bold for Courageous Patients" Program to Support Patients Living with Rare Diseases
SAN FRANCISCO, Feb. 28, 2019 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing innovative gene therapy products for patients living with serious, life-threatening rare diseases, today announced its support for Rare Disease Day® with the launch of "Be Bold for Courageous Patients," a program designed to meaningfully impact the lives of patients living with rare diseases.
Feb 27, 2019 03:01 pm ET
Audentes Therapeutics Reports Fourth Quarter 2018 and Full Year Financial Results and Provides Corporate Update
SAN FRANCISCO, Feb. 27, 2019 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing innovative gene therapy products for patients living with serious, life-threatening rare diseases, today reported its financial results for the fourth quarter and full year ended December 31, 2018 and provided an update on the company's recent achievements and anticipated upcoming milestones.
Feb 21, 2019 07:00 am ET
Audentes Therapeutics to Release Fourth Quarter and Full Year 2018 Financial Results and Provide Corporate Update on Wednesday, February 27, 2019
SAN FRANCISCO, Feb. 21, 2019 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing innovative gene therapy products for patients living with serious, life-threatening rare diseases, will host a conference call and webcast to report its fourth quarter and full year 2018 financial results and provide a corporate update on Wednesday, February 27, 2019.
Feb 20, 2019 07:00 am ET
Audentes Therapeutics to Participate in Upcoming Investor Conferences
SAN FRANCISCO, Feb. 20, 2019 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing innovative gene therapy products for patients living with serious, life-threatening rare diseases, today announced that it will participate in the following investor conferences in February and March:  
Feb 13, 2019 08:20 am ET
Report: Developing Opportunities within Dunkin' Brands Group, Murphy Oil, NII, Audentes Therapeutics, RealNetworks, and MDC Partners — Future Expectations, Projections Moving into 2019
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Dunkin' Brands Group, Inc. (NASDAQ:DNKN), Murphy Oil Corporation...
Feb 08, 2019 05:00 pm ET
Audentes Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, Feb. 8, 2019 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing innovative gene therapy products for patients living with serious, life-threatening rare diseases, announced it has granted equity awards on February 5, 2019, that were previously approved by the Compensation Committee of its Board of Directors under the Audentes Therapeutics, Inc. 2018 Equity Inducement Plan, as a material inducement to employment to ten individuals hired by Audentes in January 2019. The equity awards were approved in acco
Jan 31, 2019 07:00 am ET
Audentes Therapeutics Announces Next Steps in the Development of AT132 to Treat XLMTM Following Collaborative Initial Meeting with FDA Under RMAT Designation
SAN FRANCISCO, Jan. 31, 2019 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing innovative gene therapy products for patients living with serious, life-threatening rare diseases, today provided an update following the receipt of minutes from its Regenerative Medicine and Advanced Therapy (RMAT)/Type B meeting with the U.S. Food and Drug Administration (FDA) held in December 2018, regarding the company's lead gene therapy candidate, AT132, for the treatment of X-linked Myotubular Myopathy (XLMTM).
Jan 07, 2019 07:00 am ET
Audentes Therapeutics Reports on Recent Progress and Outlines 2019 Key Priorities
SAN FRANCISCO, Jan. 7, 2019 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing innovative gene therapy products for patients living with serious, life-threatening rare diseases, today provided an update on recent progress and the company's strategic priorities for 2019.
Jan 04, 2019 05:00 pm ET
Audentes Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, Jan. 4, 2019 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing innovative gene therapy products for patients living with serious, life-threatening rare diseases, announced it has granted equity awards on January 3, 2019, that were previously approved by the Compensation Committee of its Board of Directors under the Audentes Therapeutics, Inc. 2018 Equity Inducement Plan, as a material inducement to employment to five individuals hired by Audentes in December 2018. The equity awards were approved in acc
Jan 03, 2019 07:00 am ET
Audentes Therapeutics Appoints Eric B. Mosbrooker as Senior Vice President and Chief Commercial Officer
SAN FRANCISCO, Jan. 3, 2019 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing innovative gene therapy products for patients living with serious, life-threatening rare diseases, today announced that it has appointed Eric B. Mosbrooker as Senior Vice President and Chief Commercial Officer.  In this role, Mr. Mosbrooker is responsible for leading the development and execution of the global commercial strategy for the company's growing portfolio of gene therapy product candidates, and for building the commercial organiza
Jan 02, 2019 07:00 am ET
Audentes Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference
SAN FRANCISCO, Jan. 2, 2019 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, today announced that Matthew R. Patterson, Chairman and Chief Executive Officer, will provide a corporate overview and 2019 outlook at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco, CA.  The presentation is scheduled for Tuesday, January 8, 2019, at 3:30 pm PST.
Dec 07, 2018 05:00 pm ET
Audentes Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, Dec. 7, 2018 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing innovative gene therapy products for patients living with serious, life-threatening rare diseases, announced it has granted equity awards on December 3, 2018, that were previously approved by the Compensation Committee of its Board of Directors under the Audentes Therapeutics, Inc. 2018 Equity Inducement Plan, as a material inducement to employment to seven individuals hired by Audentes in November 2018. The equity awards were approved in a
Nov 09, 2018 08:55 am ET
Recent Analysis Shows Audentes Therapeutics, Endocyte, Bluerock Residential Growth REIT, Air Products and Chemicals, BWX Technologies, and Modine Manufacturing Market Influences — Renewed Outlook, Key
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Audentes Therapeutics, Inc. (NASDAQ:BOLD), Endocyte, Inc....
Nov 07, 2018 07:00 am ET
Audentes Therapeutics to Participate in Upcoming Investor Conferences
SAN FRANCISCO, Nov. 7, 2018 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing innovative gene therapy products for patients living with serious, life-threatening rare diseases, today announced that it will participate in the following investor conferences in November:  
Nov 06, 2018 03:01 pm ET
Audentes Therapeutics Reports Third Quarter 2018 Financial Results and Provides Corporate Update
SAN FRANCISCO, Nov. 6, 2018 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing innovative gene therapy products for patients living with serious, life-threatening rare diseases, today reported its financial results for the third quarter ended September 30, 2018 and provided an update on the company's recent achievements and upcoming milestones.
Nov 05, 2018 07:00 am ET
Audentes Therapeutics Board of Directors Appoints Co-Founder and Chief Executive Officer Matthew R. Patterson as Chairman
SAN FRANCISCO, Nov. 5, 2018 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing innovative gene therapy products for patients living with serious, life-threatening rare diseases, today announced that Co-Founder and Chief Executive Officer (CEO) Matthew R. Patterson has been appointed Chairman of the Board of Directors.  The Board of Directors also appointed Louis G. Lange, M.D., Ph.D. as Lead Independent Director.  Mr. Patterson and Dr. Lange have held board member roles since 2012 and 2015, respectively.  
Oct 30, 2018 08:00 am ET
Audentes Therapeutics to Release Third Quarter 2018 Financial Results and Provide Corporate Update on Tuesday, November 6, 2018
SAN FRANCISCO, Oct. 30, 2018 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing innovative gene therapy products for patients living with serious, life-threatening rare diseases, will host a conference call and webcast to report its third quarter 2018 financial results and provide a corporate update on Tuesday, November 6, 2018.
Oct 16, 2018 07:36 am ET
Report: Developing Opportunities within The Ensign Group, Forterra, Inc., Audentes Therapeutics, Assembly Biosciences, Capital Senior Living, and Myomo — Future Expectations, Projections Moving into 2
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of The Ensign Group, Inc. (NASDAQ:ENSG), Forterra, Inc. (NASDAQ:FRTA),...
Oct 10, 2018 08:30 pm ET
Audentes Therapeutics Announces Pricing of Public Offering of Common Stock
SAN FRANCISCO, Oct. 10, 2018 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a clinical stage biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, today announced the pricing of its underwritten public offering of 5,200,000 shares of its common stock at a price to the public of $29.00 per share.  The gross proceeds to Audentes from the offering, before deducting the underwriting discounts and commissions and other offering expenses payable by Audentes, are expected to be $150.8 mill
Oct 09, 2018 04:20 pm ET
Audentes Therapeutics Announces Proposed Public Offering of Common Stock
SAN FRANCISCO, Oct. 9, 2018 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a clinical stage biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, announced today that it intends to offer $150 million of its common stock in an underwritten public offering.  In addition, Audentes intends to grant the underwriters a 30-day option to purchase up to an additional $22.5 million of its common stock offered in the public offering at the public offering price less the underwriting discounts
Oct 03, 2018 09:00 am ET
Audentes Therapeutics Announces Co-Founder and Chief Executive Officer Matthew R. Patterson Appointed Chairman of the Alliance for Regenerative Medicine
SAN FRANCISCO, Oct. 3, 2018 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing innovative gene therapy products for patients living with serious, life-threatening rare diseases, today announced that Co-Founder and Chief Executive Officer (CEO) Matthew R. Patterson has been appointed Chairman of the Alliance for Regenerative Medicine (ARM), the international advocacy organization representing the gene and cell therapy and broader regenerative medicine sector.  Mr. Patterson has served as Vice Chairman of ARM since Augu
Sep 26, 2018 08:00 am ET
Audentes Therapeutics to Participate in Upcoming Investor Conferences
SAN FRANCISCO, Sept. 26, 2018 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing innovative gene therapy products for patients living with serious, life-threatening rare diseases, today announced that it will participate in the following investor conferences in October:  
Sep 24, 2018 08:00 am ET
Audentes Therapeutics to Present New Data from ASPIRO, the Phase 1/2 Clinical Trial of AT132 in Patients with X-Linked Myotubular Myopathy, at the 23rd International Congress of the World Muscle Socie
SAN FRANCISCO, Sept. 24, 2018 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing innovative gene therapy products for patients living with serious, life-threatening rare diseases, today announced that new interim data from ASPIRO, the Phase 1/2 clinical trial of AT132 in patients with X-linked Myotubular Myopathy (XLMTM), will be presented at the 23rd International Congress of the World Muscle Society (WMS) in Mendoza, Argentina.  The oral presentation will be given by Nancy Kuntz, MD, Principal Investigator at Lurie
Aug 29, 2018 08:00 am ET
Audentes Therapeutics to Participate in Upcoming Investor Conferences
SAN FRANCISCO, Aug. 29, 2018 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing innovative gene therapy products for patients living with serious, life-threatening rare diseases, today announced that it will participate in the following investor conferences in September:  
Aug 21, 2018 08:00 am ET
Audentes Announces Regenerative Medicine Advanced Therapy (RMAT) Designation Granted by the FDA to AT132 for the Treatment of X-Linked Myotubular Myopathy
SAN FRANCISCO, Aug. 21, 2018 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing innovative gene therapy products for patients living with serious, life-threatening rare diseases, today announced that the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to AT132 for the treatment of X-linked Myotubular Myopathy (XLMTM).
Aug 17, 2018 07:50 am ET
Factors of Influence in 2018, Key Indicators and Opportunity within AgroFresh Solutions, SMART SAND INC, Advantage Oil & Gas, Abeona Therapeutics, B. Riley Financial, and Audentes Therapeutics — New R
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of AgroFresh Solutions, Inc. (NASDAQ:AGFS), SMART SAND INC (NASDAQ:SND),...
Aug 09, 2018 08:00 am ET
Audentes Therapeutics to Present at the 2018 Wedbush PacGrow Healthcare Conference
SAN FRANCISCO, Aug. 9, 2018 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing innovative gene therapy products for patients living with serious, life-threatening rare diseases, today announced that Natalie Holles, President and Chief Operating Officer, will present at the 2018 Wedbush PacGrow Healthcare Conference in New York. The presentation is scheduled for Tuesday, August 14, 2018, at 1:55 pm ET.
Aug 07, 2018 06:00 am ET
Audentes Therapeutics Reports Second Quarter 2018 Financial Results and Provides Update on ASPIRO, the Phase 1/2 Clinical Trial of AT132 in Patients with X-Linked Myotubular Myopathy
-          Muscle biopsy data demonstrate highly efficient tissue transduction as indicated by vector copy number, robust myotubularin protein expression as assessed by western blot, and significant improvement in histology in first three treated patients at 24-week timepoint
Jul 31, 2018 08:00 am ET
Audentes to Release Second Quarter 2018 Financial Results and Provide Update on ASPIRO, the Phase 1/2 study of AT132 in Patients with X-Linked Myotubular Myopathy
SAN FRANCISCO, July 31, 2018 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing innovative gene therapy products for patients living with serious, life-threatening rare diseases, will host a conference call and webcast to report its second quarter 2018 financial results and provide an update on ASPIRO, the Phase 1/2 study of AT132 in patients with X-Linked Myotubular Myopathy.  The ASPIRO update will include 24-week clinical data and muscle biopsy results from the first three patients treated in the study. 
Jun 05, 2018 08:00 am ET
Audentes Announces Priority Medicines (PRIME) Designation Granted by the European Medicines Agency to AT132 for the treatment of X-Linked Myotubular Myopathy
SAN FRANCISCO, June 5, 2018 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing innovative gene therapy products for patients living with serious, life-threatening rare diseases, today announced that the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) designation to AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM).  The PRIME designation is intended to enhance interaction and early dialogue with developers of promising therapies to optimize development plans and speed evaluation so
May 31, 2018 08:25 am ET
Market Trends Toward New Normal in Audentes Therapeutics, Aqua Metals, BT Group, Mid-America Apartment Communities, MDC Partners, and Hexcel — Emerging Consolidated Expectations, Analyst Ratings
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Audentes Therapeutics, Inc. (NASDAQ:BOLD), Aqua Metals, Inc....
May 29, 2018 08:00 am ET
Audentes Therapeutics to Present at the Jefferies 2018 Global Healthcare Conference
SAN FRANCISCO, May 29, 2018 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing innovative gene therapy products for patients living with serious, life-threatening rare diseases, today announced that Matthew R. Patterson, Chief Executive Officer, will present at the Jefferies 2018 Global Healthcare Conference in New York, NY.  The presentation is scheduled for Tuesday, June 5, 2018, at 8:30 am ET.
May 16, 2018 11:30 am ET
Audentes Announces Continuing Positive Data from First Dose Cohort of ASPIRO, a Phase 1/2 Clinical Trial of AT132 in Patients With X-Linked Myotubular Myopathy
SAN FRANCISCO, May 16, 2018 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, today announced continuing positive data from the first dose cohort of ASPIRO, a Phase 1/2 clinical trial of AT132 in patients with X-Linked Myotubular Myopathy (XLMTM).  ASPIRO is a multicenter, multinational, open-label, ascending dose study to evaluate the safety and preliminary efficacy of AT132 in approximately 12 XLMTM patients less than five years
May 09, 2018 04:01 pm ET
Audentes Therapeutics Reports First Quarter 2018 Financial Results and Provides Corporate Update
SAN FRANCISCO, May 9, 2018 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing innovative gene therapy products for patients living with serious, life-threatening rare diseases, today reported its financial results for the first quarter ended March 31, 2018 and provided an update on the company's recent achievements and anticipated upcoming milestones.
May 09, 2018 08:00 am ET
Audentes Therapeutics to Present at the Bank of America Merrill Lynch Health Care Conference 2018
SAN FRANCISCO, May 9, 2018 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing innovative gene therapy products for patients living with serious, life-threatening rare diseases, today announced that Natalie Holles, President and Chief Operating Officer, will present at the Bank of America Merrill Lynch Health Care Conference in Las Vegas, NV.  The presentation is scheduled for Wednesday, May 16, 2018, at 11:20 am PT.
May 08, 2018 08:00 am ET
Audentes Therapeutics Announces the Promotion of Natalie Holles to President and Chief Operating Officer
SAN FRANCISCO, May 8, 2018 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq:BOLD), a biotechnology company focused on developing and commercializing innovative gene therapy products for patients living with serious, life-threatening rare diseases, today announced the promotion of Natalie Holles from Senior Vice President and Chief Operating Officer to President and Chief Operating Officer.  In this new role, Ms. Holles will oversee the day-to-day operations of the company, including research, development, manufacturing, program management and corporate development. 
May 02, 2018 08:00 am ET
Audentes Therapeutics to Release First Quarter 2018 Financial Results and Provide Corporate Update on Wednesday, May 9, 2018
SAN FRANCISCO, May 2, 2018 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing innovative gene therapy products for patients living with serious, life-threatening rare diseases, will host a conference call to report its first quarter 2018 financial results and provide a corporate update on Wednesday, May 9, 2018.
Apr 30, 2018 01:14 pm ET
Audentes Therapeutics Announces Presentation of Data at the 21st Annual Meeting of the American Society of Gene and Cell Therapy
SAN FRANCISCO, April 30, 2018 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing innovative gene therapy products for patients living with serious, life-threatening rare diseases, today announced that data related to its product candidates AT132 for the treatment of X-linked Myotubular Myopathy (XLMTM), AT342 for the treatment of Crigler Najjar Syndrome, and AT982 for the treatment of Pompe disease will be presented at the 21st Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) to be held in C
Apr 05, 2018 08:30 am ET
New Research: Key Drivers of Growth for Aqua Metals, Audentes Therapeutics, Gaming and Leisure Properties, Mammoth Energy Services, Inc., ONE Gas, and Mettler-Toledo International — Factors of Influen
NEW YORK, April 05, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Aqua Metals, Inc. (NASDAQ:AQMS), Audentes Therapeutics,...
Mar 08, 2018 03:01 pm ET
Audentes Therapeutics Reports Fourth Quarter 2017 and Full Year Financial Results and Provides Corporate Update
SAN FRANCISCO, March 8, 2018 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing innovative gene therapy products for patients living with serious, life-threatening rare diseases, today reported its financial results for the fourth quarter and full year ended December 31, 2017 and provided an update on the company's recent achievements and anticipated upcoming milestones.
Mar 07, 2018 07:35 am ET
New Research: Key Drivers of Growth for Entergy, CarMax, Verifone, Audentes Therapeutics, EZCORP, and Cabot Microelectronics — Factors of Influence, Major Initiatives and Sustained Production
NEW YORK, March 07, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Entergy Corporation (NYSE:ETR), CarMax, Inc. (NYSE:KMX),...
Mar 06, 2018 07:00 am ET
Audentes Therapeutics to Present at the Cowen 38th Annual Health Care Conference
SAN FRANCISCO, March 6, 2018 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing innovative gene therapy products for patients living with serious, life-threatening rare diseases, today announced that Matthew R. Patterson, President and Chief Executive Officer, will present at the Cowen 38th Annual Health Care Conference in Boston, MA.  The presentation is scheduled for Tuesday, March 13, 2018, at 10:00 am ET.
Mar 01, 2018 07:00 am ET
Audentes Therapeutics to Release Fourth Quarter and Full Year 2017 Financial Results and Provide Corporate Update on Thursday, March 8, 2018
SAN FRANCISCO, March 1, 2018 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing innovative gene therapy products for patients living with serious, life-threatening rare diseases, will host a conference call to report its fourth quarter and full year 2017 financial results and provide a corporate update on Thursday, March 8, 2018.
Feb 28, 2018 07:00 am ET
Audentes Therapeutics Joins Global Organizations In Recognizing Rare Disease Day® 2018
SAN FRANCISCO, Feb. 28, 2018 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing innovative gene therapy products for patients living with serious, life-threatening rare diseases, today announced its support for Rare Disease Day®.  The global theme of this year's Rare Disease Day is research.  Rare disease research contributes to the development of diagnostic tools, treatments and cures, as well as improved health and social care for patients and their families.  
Feb 12, 2018 07:00 am ET
Audentes Therapeutics Announces Dosing of First Patient in VALENS, a Phase 1/2 Clinical Trial of AT342 for the treatment of Crigler-Najjar Syndrome
SAN FRANCISCO, Feb. 12, 2018 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, today announced it has commenced dosing of patients in VALENS, a Phase 1/2 clinical trial of its product candidate AT342 for the treatment of Crigler-Najjar Syndrome.  VALENS is a multicenter, multinational, open-label, randomized, ascending dose study designed to evaluate the safety and efficacy of AT342 in approximately 12 Crigler-Najjar patients one
Feb 08, 2018 07:00 am ET
Audentes Therapeutics to Present at the LEERINK Partners 7th Annual Global Healthcare Conference
SAN FRANCISCO, Feb. 8, 2018 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, today announced that Matthew R. Patterson, President and Chief Executive Officer, will present at the LEERINK Partners 7th Annual Global Healthcare Conference in New York, NY.  The presentation is scheduled for Thursday, February 15, 2018, at 10:30 am ET.
Feb 06, 2018 06:30 pm ET
Audentes Therapeutics Announces Selection of Optimized Clinical Development Candidate for Pompe Disease Program
SAN FRANCISCO, Feb. 6, 2018 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, today announced it has selected an optimized clinical development candidate for its Pompe disease program.  Data supporting the selection were presented today during a general session at the 14th Annual WORLDSymposium 2018 in Poster #123, titled: "A Novel Hybrid Promoter Directing AAV-mediated Expression of Acid Alpha-Glucosidase to Liver, Muscle, and CN
Jan 29, 2018 03:01 pm ET
Audentes Therapeutics Announces the Closing of its Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
SAN FRANCISCO, Jan. 29, 2018 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a clinical stage biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, today announced the closing of its previously announced underwritten public offering of 6,612,500 shares of its common stock at a price to the public of $35.00 per share before underwriting discounts and commissions, which included the exercise in full by the underwriters of their option to purchase 862,500 additional shares of common sto
Jan 24, 2018 06:43 pm ET
Audentes Therapeutics Announces Pricing of Public Offering of Common Stock
SAN FRANCISCO, Jan. 24, 2018 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a clinical stage biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, today announced the pricing of its underwritten public offering of 5,750,000 shares of its common stock at a price to the public of $35.00 per share before underwriting discounts and commission.  The gross proceeds to Audentes from the offering, before deducting the underwriting discounts and commissions and other offering expenses payabl
Jan 23, 2018 03:01 pm ET
Audentes Therapeutics Announces Proposed Public Offering of Common Stock
SAN FRANCISCO, Jan. 23, 2018 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a clinical stage biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, announced today that it intends to offer $150.0 million of its common stock in an underwritten public offering.  In addition, Audentes intends to grant the underwriters a 30-day option to purchase up to an additional $22.5 million of its common stock offered in the public offering at the public offering price less the underwriting discoun
Jan 03, 2018 07:00 am ET
Audentes Therapeutics to Present at the 36th Annual J.P. Morgan Healthcare Conference
SAN FRANCISCO, Jan. 3, 2018 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, today announced that Matthew R. Patterson, President and Chief Executive Officer, will provide a corporate overview and 2018 outlook at the 36th Annual J.P. Morgan Healthcare Conference in San Francisco, CA.  The presentation is scheduled for Wednesday, January 10, 2018, at 2:30 pm PT.
Dec 13, 2017 07:00 am ET
Audentes Therapeutics Appoints Mark A. Goldberg, M.D. to its Board of Directors
SAN FRANCISCO, Dec. 13, 2017 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, today announced the appointment of Mark A. Goldberg, M.D. to its board of directors.
Nov 21, 2017 07:00 am ET
Audentes Therapeutics Announces Publication of Data from RECENSUS, a Retrospective Medical Record Review of Patients With X-Linked Myotubular Myopathy
SAN FRANCISCO, Nov. 21, 2017 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, today announced the publication of "A Multicenter, Retrospective Medical Record Review of X-Linked Myotubular Myopathy: The RECENSUS Study," in Muscle & Nerve.  This publication from RECENSUS, a study sponsored by Audentes, expands upon the data first presented at the Muscular Dystrophy Association (MDA) Scientific Conference in March 2017, and rein
Nov 16, 2017 08:00 am ET
Audentes Therapeutics to Present at Upcoming Investor Conferences
SAN FRANCISCO, Nov. 16, 2017 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, today announced that Matthew R. Patterson, President and Chief Executive Officer, will present at the following upcoming investor conferences:
Nov 14, 2017 04:01 pm ET
Audentes Therapeutics Reports Third Quarter 2017 Financial Results and Provides Corporate Update
SAN FRANCISCO, Nov. 14, 2017 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, today reported its financial results for the quarter ended September 30, 2017, and provided an update on the company's recent achievements and anticipated upcoming milestones.
Nov 07, 2017 08:00 am ET
Audentes Therapeutics to Release Third Quarter 2017 Financial Results and Provide Corporate Update on Tuesday, November 14, 2017
SAN FRANCISCO, Nov. 7, 2017 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, will host a conference call to report its third quarter 2017 financial results and provide a corporate update on Tuesday, November 14, 2017.
Sep 27, 2017 09:00 am ET
Audentes Therapeutics Announces Rare Pediatric Disease and Fast Track Designations for AT132 for the Treatment of X-Linked Myotubular Myopathy
SAN FRANCISCO, Sept. 27, 2017 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease and Fast Track designations for AT132, the company's gene therapy product candidate being developed to treat X-Linked Myotubular Myopathy (XLMTM).  In addition to these two new designations, AT132 has also received Orphan Drug designation from both the F
Sep 21, 2017 09:00 am ET
Audentes Therapeutics Announces Dosing of First Patient in ASPIRO, a Phase 1/2 Clinical Trial of AT132 for the Treatment of X-Linked Myotubular Myopathy
SAN FRANCISCO, Sept. 21, 2017 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, today announced it has commenced dosing of patients in ASPIRO, a Phase 1/2 clinical trial of AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM).  ASPIRO is a multicenter, multinational, open-label, ascending dose study to evaluate the safety and preliminary efficacy of AT132 in approximately twelve XLMTM patients less than five years of ag
Sep 19, 2017 09:00 am ET
Audentes Therapeutics to Present at Upcoming Investor Conferences
SAN FRANCISCO, Sept. 19, 2017 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, today announced that Matthew R. Patterson, President and Chief Executive Officer, will present at the following upcoming investor conferences:
Aug 10, 2017 09:00 am ET
Audentes Therapeutics Reports Second Quarter 2017 Financial Results and Provides Corporate Update
SAN FRANCISCO, Aug. 10, 2017 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, today reported its financial results for the quarter ended June 30, 2017, and provided an update on the company's recent achievements and anticipated upcoming milestones.
Jul 18, 2017 09:00 am ET
Audentes Therapeutics Announces Appointment of Fulvio Mavilio, Ph.D. to Vice President Scientific Affairs, Europe
SAN FRANCISCO, July 18, 2017 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, today announced the appointment of Fulvio Mavilio, Ph.D. to Vice President Scientific Affairs, Europe. Dr. Mavilio will be based in Paris.
Jun 28, 2017 09:00 am ET
Audentes Therapeutics Announces Participation in Upcoming Investor Conferences
SAN FRANCISCO, June 28, 2017 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, today announced its participation in the following upcoming investor conferences:
Jun 13, 2017 09:00 am ET
Audentes Therapeutics Appoints Jennifer Jarrett to Board of Directors
SAN FRANCISCO, June 13, 2017 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, today announced the appointment of Jennifer Jarrett to its board of directors.
May 11, 2017 09:00 am ET
Audentes Therapeutics Reports First Quarter 2017 Financial Results and Provides Corporate Update
SAN FRANCISCO, May 11, 2017 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, today reported its financial results for the quarter ended March 31, 2017, and provided an update on the company's recent achievements and anticipated upcoming milestones.
May 10, 2017 09:00 am ET
Audentes Therapeutics to Present At Upcoming Investor Conferences
SAN FRANCISCO, May 10, 2017 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, today announced that Matthew R. Patterson, President and Chief Executive Officer, will present at the following upcoming investor conferences:
May 08, 2017 09:00 am ET
Audentes Therapeutics Announces Appointment of John T. Gray, Ph.D. to Senior Vice President and Chief Scientific Officer
SAN FRANCISCO, May 8, 2017 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, today announced the appointment of John T. Gray, Ph.D. to Senior Vice President and Chief Scientific Officer.  Dr. Gray joined Audentes in 2014 as Vice President, Research and Development, and has successfully built and led teams across the Company's molecular biology, process development, and nonclinical research and development functions. 
May 03, 2017 09:00 am ET
Audentes Therapeutics Announces Presentation of Data at the American Society of Gene and Cell Therapy Annual Meeting
SAN FRANCISCO, May 3, 2017 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, today announced that data related to its product candidates AT132 for the treatment of X-linked Myotubular Myopathy, and AT342 for the treatment of Crigler Najjar Syndrome, will be presented at the 20th Annual Meeting of the American Society of Gene and Cell Therapy to be held in Washington, DC on May 10-13th, 2017.  Four abstracts will be presented durin
Apr 18, 2017 07:44 pm ET
Audentes Therapeutics Announces Pricing of Public Offering of Common Stock
SAN FRANCISCO, April 18, 2017 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, today announced the pricing of its underwritten public offering of 5,200,000 shares of its common stock at a price to the public of $14.50 per share before underwriting discounts and commission. The gross proceeds to Audentes from the offering, before deducting the underwriting discounts and commissions and other offering expenses payable by Audentes,
Apr 17, 2017 05:01 pm ET
Audentes Therapeutics Announces Proposed Public Offering of Common Stock
SAN FRANCISCO, April 17, 2017 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, today announced that it intends to offer and sell 4,750,000 shares of its common stock in an underwritten public offering.  In addition, Audentes intends to grant the underwriters a 30-day option to purchase up to an additional 712,500 shares of common stock.  The offering is subject to market and other conditions, and there can be no assurance as to w
Apr 17, 2017 09:00 am ET
Audentes Therapeutics to Present at the ARM 5th Annual Cell & Gene Therapy Investor Day
SAN FRANCISCO, April 17, 2017 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, today announced that Matthew R. Patterson, President and Chief Executive Officer, will present a corporate overview at the Alliance for Regenerative Medicine's 5th Annual Cell & Gene Therapy Investor Day in Boston, MA.  The presentation is scheduled for Thursday, April 27, 2017, at 9:55 am ET.
Apr 03, 2017 09:00 am ET
Audentes Therapeutics Announces FDA Clearance of Investigational New Drug Application for AT132 to Treat X-Linked Myotubular Myopathy
SAN FRANCISCO, April 3, 2017 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for AT132, the Company's gene therapy product candidate to treat X-Linked Myotubular Myopathy (XLMTM). The IND is now active and Audentes plans to initiate ASPIRO, the multicenter, multinational, open-label, ascending dose Phase 1/
Mar 20, 2017 09:00 am ET
Audentes Therapeutics Announces Presentation Of Data From RECENSUS, A Medical Chart Review Of Patients With X-Linked Myotubular Myopathy (XLMTM)
SAN FRANCISCO, March 20, 2017 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, today announced that data from RECENSUS, a medical chart review of patients with X-linked Myotubular Myopathy (XLMTM), will be presented at the 2017 Muscular Dystrophy Association (MDA) Scientific Conference, which will be held in Arlington, Virginia from March 19 to 22, 2017. These data provide new insights into the significant medical burden for chil
Mar 09, 2017 08:00 am ET
Audentes Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update
SAN FRANCISCO, March 9, 2017 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, today reported its financial results for the fourth quarter and full year ended December 31, 2016, and provided an update on the company's recent achievements and anticipated upcoming milestones.
Mar 01, 2017 08:00 am ET
Audentes Therapeutics Announces Commencement of LUSTRO, a Clinical Assessment and Phase 1/2 Run-in Study of Patients with Crigler-Najjar Syndrome
SAN FRANCISCO, March 1, 2017 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, today announced the commencement of LUSTRO, a prospective study designed to characterize the disease course in patients living with Crigler-Najjar Syndrome.  LUSTRO will evaluate subjects prior to potential enrollment in VALENS, the planned Phase 1/2 clinical study to evaluate the safety and preliminary efficacy of AT342, the Audentes product candidate
Feb 07, 2017 08:00 am ET
Audentes Therapeutics to Present at Upcoming Investor Conferences
SAN FRANCISCO, Feb. 7, 2017 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, today announced that Matthew R. Patterson, President and Chief Executive Officer, will present at the following upcoming investor conferences:
Feb 01, 2017 08:00 am ET
Audentes Therapeutics Announces FDA Clearance of Investigational New Drug Application for AT342 to Treat Crigler-Najjar Syndrome
SAN FRANCISCO, Feb. 1, 2017 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for AT342, the Company's gene therapy product candidate to treat Crigler-Najjar Syndrome. The IND is now active and Audentes plans to initiate VALENS, the multicenter, multinational, open-label, ascending dose phase 1/2 clinical stu
Jan 09, 2017 08:00 am ET
Audentes Therapeutics Provides Full Year 2017 Strategic Outlook and Financial Guidance
SAN FRANCISCO, Jan. 9, 2017 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, today provided its full-year 2017 strategic outlook and financial guidance.
Jan 04, 2017 08:00 am ET
Audentes Therapeutics to Present at the 35th Annual J.P. Morgan Healthcare Conference
SAN FRANCISCO, Jan. 4, 2017 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, today announced that Matthew R. Patterson, President and Chief Executive Officer, will provide a corporate overview and 2017 outlook at the 35th Annual J.P. Morgan Healthcare Conference in San Francisco, CA.  The presentation is scheduled for Tuesday, January 10, 2017, at 5:00 pm PST.
Dec 13, 2016 08:00 am ET
Audentes Therapeutics Appoints Julie Anne Smith to Board of Directors
SAN FRANCISCO, Dec. 13, 2016 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, today announced the appointment of Julie Anne Smith to its board of directors.
Nov 29, 2016 08:00 am ET
Audentes Therapeutics Announces Initiation of Large-scale cGMP Production at its Gene Therapy Manufacturing Facility
SAN FRANCISCO, Nov. 29, 2016 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, today announced it has successfully initiated large-scale cGMP (current Good Manufacturing Practice) production runs in its new, state-of-the-art manufacturing facility.
Nov 21, 2016 08:00 am ET
Audentes Therapeutics to Attend Piper Jaffray 28th Annual Healthcare Conference
SAN FRANCISCO, Nov. 21, 2016 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, today announced its plans to attend the Piper Jaffray 28th Annual Healthcare Conference being held at the Lotte New York Palace in New York, NY on November 29-30, 2016. 
Nov 10, 2016 08:00 am ET
Audentes Therapeutics Reports Third Quarter 2016 Financial Results and Provides Corporate Update
SAN FRANCISCO, Nov. 10, 2016 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, today reported its financial results for the quarter ended September 30, 2016 and provided an update on the company's recent achievements and upcoming events.
Sep 21, 2016 09:00 am ET
Audentes Therapeutics to Present at Upcoming Investor Conferences
SAN FRANCISCO, Sept. 21, 2016 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, today announced that Matthew R. Patterson, President and Chief Executive Officer, will present at the following upcoming investor conferences:
Aug 31, 2016 05:05 pm ET
Audentes Therapeutics Reports Second Quarter 2016 Financial Results and Provides Corporate Update
SAN FRANCISCO, Aug. 31, 2016 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, today reported its financial results for the quarter ended June 30, 2016 and provided an update on the company's recent achievements and upcoming events.
Aug 17, 2016 09:00 am ET
Audentes Therapeutics Announces First Patient Enrolled in the INCEPTUS Clinical Assessment Study of XLMTM
SAN FRANCISCO, Aug. 17, 2016 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, today reported that the first patient has been enrolled in INCEPTUS, a prospective study designed to characterize the disease presentation in children living with X-Linked Myotubular Myopathy (XLMTM). The study is evaluating subjects prior to potential enrollment in ASPIRO, the planned Phase 1/2 clinical study intended to evaluate the safety and prelimi
Aug 08, 2016 09:00 am ET
Audentes Therapeutics to Present at the 2016 Wedbush PacGrow Healthcare Conference
SAN FRANCISCO, Calif., Aug. 8, 2016 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening diseases, today announced that Matthew R. Patterson, President and Chief Executive Officer, will present at the 2016 Wedbush PacGrow Healthcare Conference on Wednesday, August 17, 2016 at 10:20 am ET.

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.